MNG1253
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.373
- TGF_BETA_SIGNALING+0.337
- DNA_REPAIR+0.332
- OXIDATIVE_PHOSPHORYLATION+0.294
- ADIPOGENESIS+0.291
- UNFOLDED_PROTEIN_RESPONSE+0.267
- MYC_TARGETS_V1+0.244
- PI3K_AKT_MTOR_SIGNALING+0.219
- PEROXISOME+0.196
- UV_RESPONSE_UP+0.189
Top 10 suppressed
- ANGIOGENESIS-0.488
- TNFA_SIGNALING_VIA_NFKB-0.354
- KRAS_SIGNALING_UP-0.315
- E2F_TARGETS-0.314
- G2M_CHECKPOINT-0.296
- KRAS_SIGNALING_DN-0.261
- INFLAMMATORY_RESPONSE-0.234
- SPERMATOGENESIS-0.217
- COMPLEMENT-0.210
- ALLOGRAFT_REJECTION-0.208
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG659 | — | — | 0.826 |
| 2 | DRR168596 | — | — | 0.754 |
| 3 | EA6A086B-F655-47E8-9E70-8A2D36FC2AE1 | — | — | 0.750 |
| 4 | A0DA6087-9D43-41F9-8569-9F9320E4A9E8 | — | — | 0.725 |
| 5 | MNG910 | — | — | 0.718 |
| 6 | BS_G3RJTBZD | high-grade glioma | — | 0.718 |
| 7 | MNG977 | — | — | 0.704 |
| 8 | MNG1043 | — | — | 0.702 |
| 9 | F2FCC449-3487-474C-82A6-8F2ED71E41BC | — | — | 0.694 |
| 10 | SJBT031392_D1.RNA-Seq | EPN | EPN Tumor | 0.693 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.373 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.337 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.332 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.294 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.291 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.267 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.244 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.219 | Inavolisib | — uncovered |
| PEROXISOME | 0.196 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.189 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.164 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.146 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.144 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.134 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.133 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.130 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.105 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.082 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.076 | Inavolisib | — uncovered |
| APOPTOSIS | 0.069 | Idelalisib | — uncovered |